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patients’ lifetimes. Duration of treatment was assumed to be 5 years, before switching 
to a basal insulin regimen. Changes were made to the base-case assumptions. First, 
the utility change per BMI unit gained (in patients with a BMI > 25 kg/m2) was 
decreased from −0.01 to −0.0061. Second, the treatment duration was increased from 
5 to 10 years. All other variables were kept constant. RESULTS: In the comparison 
with rosiglitazone, liraglutide was associated with a base-case incremental cost-effec-
tiveness ratio (ICER) of £6226 per QALY gained, which increased to £7545 with BMI 
utility changes and to £16,477 when the treatment duration was increased. Similar 
increases were seen for comparisons with glimepiride (£13,257 (base case) to £25,343 
(BMI utility change) and £38,368 (10-year treatment)) and sitagliptin (£9,851 [base 
case] to £14,616 [BMI changes] and £17,089 [10-year treatment]). CONCLUSIONS: 
Increasing the treatment duration and decreasing the impact of BMI on quality of life 
increased the ICER of liraglutide versus comparators. Liraglutide was shown to be 
cost-effective in dual therapy (assuming a threshold of £20,000 per QALY gained) 
versus rosiglitazone and sitagliptin in all three scenarios (base case, BMI utility 
changes, and 10-year treatment).
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OBJECTIVES: Analysis of the post-interventional follow-up of the UKPDS found that 
the beneﬁ ts of intensive therapy persisted even 10 years after the trial, a ﬁ nding 
consistent with “metabolic memory” (i.e., early metabolic status inﬂ uences long-term 
outcomes). We assessed the potential impact of “metabolic memory” on the cost-
effectiveness of intensive versus conventional care in Sweden. METHODS: We used 
the Economic and Health Outcomes (ECHO)-T2DM model to simulate lifetime health 
outcomes (including QALYs) and medical costs for 500 cohorts of 2000 newly diag-
nosed patients. In each cohort, patients were randomized to intensive or conventional 
care and HbA1c treatment effects corresponding to the UKPDS study were applied 
for the ﬁ rst 10 years. Consistent with ﬁ ndings from the follow-up study, HbA1c values 
were assumed to converge by year 10. Subsequently, in the intensive care arm, “meta-
bolic memory” effects (reduced risk for certain microvascular and macrovascular 
events and mortality) were applied. Two sets of “metabolic memory” effects from the 
UKPDS follow-up study were used: those observed in the sulfonylurea/insulin sub-
sample and those observed in the metformin subsample. a scenario assuming no 
“metabolic memory” effects was simulated for comparison. Unit costs were derived 
from the Swedish literature (modeling studies and a regression analysis of inpatient 
care costs based on administrative hospital data linked to the Swedish National 
Diabetes Register). RESULTS: Including “metabolic memory” had a large effect on 
the cost-effectiveness estimates. The incremental cost-effectiveness ratio declined from 
SEK2,387,292 (~c250,000) without “metabolic memory” to SEK731,308 (~c75,000) 
assuming effects from the sulfonylurea/insulin sample and to SEK445,425 (~c45,000) 
assuming effects from the metformin sample. CONCLUSIONS: These results suggest 
that good glycemic control early in the disease continuum may confer signiﬁ cant 
medical cost savings over the long term. Evaluations of the cost-effectiveness of 
intensive glycemic control in newly diagnosed patients should potentially consider the 
health and cost consequences of “metabolic memory.”
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OBJECTIVES: This study aimed to assess cost-effectiveness of treatment with liraglu-
tide added to a standard therapy with metformin (MET) or/and sulphonylurea (SU) 
compared with rosiglitazone and exenatide. METHODS: Our study used a health 
economic model (the CORE Diabetes Model) to project the long-term costs and clini-
cal outcomes of liraglutide based on clinical data from LEAD-1 trial: liraglutide + SU 
versus rosiglitazone + SU; and LEAD-6 trial: liraglutide + MET+/−SU versus exenatide 
+ MET+/−SU. The analysis was performed from the Slovak health-care services payer’s 
perspective in a 20-year time horizon. The analysis used health-state utility values 
from published sources to assess the effect of treatment on QALYs. The unit costs of 
treatment and complications were derived from published sources and ofﬁ cial tariff 
lists for health-care services paid by public payer. All ﬁ gures are shown in EUR. 
RESULTS: QALYs increased with liraglutide 1.2 mg + SU versus SU + rosiglitazone 
4 mg by 0.203. Total costs increased by c2561 resulting in incremental costs per 
QALY of c12,615. The incremental cost-effectiveness ratio for liraglutide 1.8 mg + 
MET+/−SU versus exenatide 10 μg + MET+/−SU was estimated at c24,013 per QALY 
gained (QALYs increased by 0.112). CONCLUSIONS: Using the CORE Diabetes 
Model and data from the LEAD 1 and LEAD 6 trials treatment with liraglutide is a 
cost-effective intervention compared with both rosiglitazone and exenatide. Sensitivity 
analysis showed the results are only moderately changing when altering the key 
parameters and assumptions.
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BACKGROUND: Unlike most other antihyperglycemic drugs, glucagon-like peptide 
1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. 
In a randomized clinical trial (RCT) over 26 weeks reported by Buse et al. (2009), the 
novel GLP-1 agonist liraglutide (1.8 mg once daily, OD) was found to be signiﬁ cantly 
more effective than exenatide (10 μg twice daily) in terms of HBA1c reduction. 
OBJECTIVES: To compare, from a German payer’s (SHI) perspective, the long-term 
clinical and cost-effectiveness of liraglutide (1.8 mg OD) versus exenatide (10 μg BID) 
in T2D patients, based on data from the randomized clinical trial (RCT) by Buse et 
al. 2009. METHODS: The CORE Diabetes Model (CDM) was applied using RCT 
data. The model was calibrated to RCT baseline characteristics and background 
mortality in a German diabetes population, applying epidemiological data from long-
term studies including UKPDS and Framingham to project morbidity and mortality 
of T2DM. Unit costs for direct costs were applied from an SHI perspective for year 
2009. a discounting rate of 3% was used for costs and clinical effects. For hypothetical 
cohorts of 1000 patients, each followed for 20 years, patients were assumed to be 
maintained on liraglutide and exenatide, respectively, for 5 years and subsequently 
switched to insulin. Costs and effects were projected over a 20-year time horizon. 
RESULTS: Estimated 20-year survival rates were higher for liraglutide 1.8 mg once 
daily (36.8%) compared to exenatide 10 μg administered twice daily (35.6%), and 
cumulative costs were c46,308 (liraglutide) and c45,025 (exenatide), respectively. 
Base-case ICERs were c16,632 per life-year gained for liraglutide versus exenatide, 
and c11,606 for liraglutide versus exenatide per QALY gained. Sensitivity analyses 
indicated robustness of ﬁ ndings. CONCLUSIONS: Long-term projections combining 
RCT data with the CDM strongly suggest an acceptable to attractive cost-effectiveness 
of liraglutide compared to exenatide according to currently prevailing standards.
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OBJECTIVES: To assess the long-term cost-effectiveness of treatment with liraglutide on 
top of standard therapy with metformin (MET) compared with sulphonylurea (SU) in 
people with type 2 diabetes. METHODS: The extensively published and validated CORE 
Diabetes Model was populated with the clinical data from LEAD 2: liraglutide + MET 
versus SU + MET. The analysis was performed from the polish health-care services payer’s 
perspective. a 20-year time horizon was chosen to reﬂ ect the costs and outcomes of dia-
betes as these are often only seen in the later stages of the disease. The analysis used 
health-state utility values from published sources to assess the effect of treatment on 
QALYs. The unit costs of treatment and complications were derived from published 
sources or based on expert opinion survey and Polish ofﬁ cial tariff lists for health-care 
services paid by public payer. All ﬁ gures are shown in EURO (1 EURO = 3.9 PLN). 
RESULTS: QALYs increased with liraglutide 1.2 mg + MET versus SU + MET by 0.191. 
Total costs increased by c3,349 resulting in incremental costs per QALY of c17,565. The 
incremental cost-effectiveness ratio for liraglutide 1.8 mg + MET versus SU + MET was 
estimated at c24,842 per QALY gained (QALYs increased by 0.207). Sensitivity analysis 
showed the results to be moderately changing when altering the key parameters and 
assumptions (for liraglutide 1.2 mg range from 12,944 to c30,275/QALY). CONCLU-
SIONS: Treatment with liraglutide is a cost-effective intervention compared with sulpho-
nylurea and is likely to represent good value for money in Polish setting.
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OBJECTIVES: This study evaluates the long-term economic consequences of saxagliptin 
versus sulfonylurea (SU, glipizide) as second-line therapy when used in combination with 
metformin (MET) after failure of monotherapy treatment with MET, in patients with 
type 2 diabetes mellitus (T2DM) in Germany. METHODS: A published discrete event 
simulation model with a ﬁ xed time increment was used and set to a 40-year (life-) time 
horizon. Disease progression was modeled using evidence from the UK Prospective 
Diabetes Study (UKPDS 68). The treatment sequence matched that of published guide-
lines, and efﬁ cacy and safety data were derived from published sources. The model 
assumes that quality-adjusted life-years (QALYs) are affected by complications and 
hypoglycaemic events over a lifetime. As such costs and utility decrements for macro- 
and micro-vascular complications, and adverse events such as severe hypoglycaemia are 
included. Costs were speciﬁ c to the German setting where SUs are generic. Costs and 
effects were discounted annually at 3%. The perspective of the national sick funds was 
taken, and recommendations from the Institute for Quality and Efﬁ ciency in Health 
Care (IQWiG) were considered. RESULTS: Treatment with saxagliptin + MET was 
